Alzamend Neuro Inc (NASDAQ: ALZN) might soon succeed in its mission to support the Alzheimer’s disease community. Ault Global Holdings Inc (NYSEAMERICAN: DPW) disclosed the above information today. It has focused on developing products to help treat the different persons struggling with conditions such as Alzheimer’s disease and dementia. Alzamend will soon initiate its Phase 1 clinical study of AL001, but if the FDA approves the investigational new drug (“IND”), the application is submitted. It believes research to be the cornerstone behind any true innovation.
Alzamend determined to make a difference
Alzamend dismisses the common misconception of dementia as a normal part of aging and mentions several symptoms associated with cognitive and neurological impairments. It refers to Alzheimer’s disease as the most common form of dementia. The company recognizes the many lives lost to the deadly condition and aspires to make a difference through its latest research and product development efforts. Patients suffer a lot before meeting their demise, and that ranges from diminished personalities and erased memories.
The Chief Executive Officer of Alzamend Stephan, Jackman, opines, “This IND submission represents a key milestone for Alzamend as we continue to advance our proprietary pipeline. We believe AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating Alzheimer’s disease and other neurodegenerative diseases and psychiatric disorders.”
Jackman says that they will soon unveil more details on the market opportunity and the timeline, but after the FDA gives them the green light. The company’s preclinical data indicates the AL001 treatment’s capabilities, including toning down depression, cognitive deficits, and irritability in APPSWE/PS1dE9 mice.
The AL001 treatment works better than most lithium carbonate treatments. This assertion is based on its impact on irritability, memory, and associative learning.